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Background: The stress of a breast cancer diagnosis and its treatment can produce a variety of psychosocial
sequelae including impaired immune responses. Mindfulness Based Stress Reduction (MBSR) is a structured
complementary program that incorporates meditation, yoga and mind-body exercises. Despite promising empirical
evidence for the efficacy of MBSR, there is a need for randomized controlled trials (RCT). There is also a need for
RCTs investigating the efficacy of psychosocial interventions on mood disorder and immune response in women
with breast cancer. Therefore, the overall aim is to determine the efficacy of a Mindfulness Based Stress Reduction
(MBSR) intervention on well-being and immune response in women with breast cancer.
Methods and design: In this RCT, patients diagnosed with breast cancer, will consecutively be recruited to
participate. Participants will be randomized into one of three groups: MBSR Intervention I (weekly group sessions +
self-instructing program), MBSR Intervention II (self-instructing program), and Controls (non-MBSR). Data will be
collected before start of intervention, and 3, 6, and 12 months and thereafter yearly up to 5 years. This study may
contribute to evidence-based knowledge concerning the efficacy of MBSR to support patient empowerment to
regain health in breast cancer disease.
Discussion: The present study may contribute to evidence-based knowledge concerning the efficacy of
mindfulness training to support patient empowerment to regain health in a breast cancer disease. If MBSR is
effective for symptom relief and quality of life, the method will have significant clinical relevance that may generate
standard of care for patients with breast cancer.
Trial registration: ClinicalTrials.gov: NCT01591915
Keywords: Breast cancer, Mindfulness based stress reduction, Randomized controlled trials, Well-beingBackground
Breast cancer is one of the most feared diseases among
women, and for many women a breast cancer diagnosis
and its subsequent treatment are accompanied by deal-
ing with a spectrum of physical and psychological chal-
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distribution, and reproduction in any mediumpsychological morbidity [3], and up to 30% of women
diagnosed with breast cancer develop mood disorder,
either anxiety or depressive symptoms, within one year
of diagnosis [4,5]. While breast cancer is a major stressor
for any woman, there is great variability in women’s
emotional responses and their ability to mobilize the re-
sources to cope with distress. However, although levels
of distress tend to decrease over time, a subset of
women with breast cancer remain highly distressed [6,7].
A growing area of interest is the personal growth and
transformation of individuals as they adjust to a life-ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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trates that many people experience significant personal
growth despite severe trauma or disease [8,9]. Notwith-
standing recurrent breast cancer, women who view their
disease as a challenge and an opportunity for personal
change are able to create wellness by being in the
present moment [10].
The stress of a breast cancer diagnosis and its treat-
ment can produce a variety of psychosocial sequelae in-
cluding impaired immune responses [11]. An increasing
body of research indicates that stress-related psycho-
social factors are associated with higher cancer incidence
and higher mortality [12]. Data suggest that psycho-
logical stress has a significant negative effect on cellular
immune responses, such as lowered natural killer cells
(NK cells) and T lymphocytes (T cells) [13]. Previous re-
search indicates that NK and T cells are sensitive to dif-
ferent aspects of the stress response in women with
breast cancer [14]. In addition, T cells have been linked
to recurrence [15] and survival [16]. Other important
parameters are cytokines, such as interleukin-6 (IL-6)
and interleukin-8 (IL-8), which independently show cor-
relations with breast cancer disease stage and progres-
sion [17-20].
The recognition of psychosocial needs in cancer pa-
tients has led to the development of psychosocial inter-
ventions, indicating a variety of positive effects on
coping, quality of life, emotional and functional adjust-
ment [21,22]. The literature on psychosocial interven-
tions for cancer fails to meet criteria for establishing
treatment efficacy and does not address issues of cost-
effectiveness [23]. Although evidence suggests beneficial
effects of psychosocial interventions [21,22], the physio-
logical benefits for breast cancer patients remain unclear
[24]. Furthermore, there are no existing large-scale stud-
ies prospectively investigating the efficacy of psycho-
social intervention on coping and immune response in
women with breast cancer [24].
Mindfulness Based Stress Reduction (MBSR) is a stan-
dardized program incorporating mindfulness meditation,
yoga practices and other techniques designed to reduce
suffering and improve health and well-being in patients
with a wide range of chronic pain and stress disorders
[25-27]. MBSR has also been shown to improve mood
and reduce symptoms of stress in mixed groups of can-
cer patients [28]. The primary goal of MBSR is to de-
velop the capacity to be aware in each moment, by
“paying attention in a particular way: on purpose, in the
present moment, and non-judgmentally” [25]. MBSR is a
structured group-formatted 8-week course, attended
once a week by patients for an average of 2 hours, to-
gether with daily practice of homework assignments.
While noting the efficacy of MBSR on different patient
populations, several reviews have pointed out the inhe-rent methodological problems in the published studies
[29,30]. Two systematic reviews of MBSR interventions
for the treatment of anxiety and depression emphasize
the methodological shortcomings which create uncer-
tainties about the efficacy of treatment. The reviewed
studies that reported a statistically significant reduction
in anxiety and depression did not include control groups
or follow-up data, and future studies with improved
methodologies are needed to test the efficacy of the
mindfulness component of the intervention [31,32].
The MBSR program was shown to have beneficial
effects on immune function, reduced cortisol levels, im-
proved Quality of Life (QoL), and increased coping
effectiveness in a non-randomized group of women with
breast cancer as compared with women who received
the usual care [33]. A recent randomized study [34]
showed that cancer patients who received a mindfulness
intervention reported less perceived stress and posttrau-
matic avoidance symptoms and increased positive states
of mind. This study indicates that the improvements in
psychological well-being resulting from the MBSR inter-
vention could have been explained in terms of increased
levels of mindfulness. Other study results indicate a
positive adjustment of cortisol levels as a result on
MBSR program [35]. Evidence from uncontrolled studies
of breast and prostate cancer patients also suggests that
MBSR improved QoL and decreased stress symptoms
[36], and altered cortisol and immune patterns [37].
Study results suggest that MBSR may influence the
functioning of the hypothalamic-pituitary-adrenocortical
(HPA) axis [35,38]. These pilot data from studies investi-
gating the relationships between MBSR and hormone
levels highlight the need for better-controlled studies in
this area [38]. These results raise important questions as
to whether mindfulness based interventions actually
enhance mindfulness and whether such changes in
mindfulness are related to positive outcome in the ex-
perience of health, strengthened immune system or
disease-free survival.
Despite promising empirical evidence that the efficacy
of MBSR improves mood and reduces symptoms of
stress, there is a need for randomized, controlled studies
including homogenous patient populations and using re-
producible and stringent methodological procedures. In
addition to self-reported psychosocial and functional
measures of health and illness, assessment of biological
markers are also needed in future mindfulness based in-
terventions [30].
Aim and outcome measurements
The overall aim is to determine the efficacy of a Mind-
fulness Based Stress Reduction (MBSR) intervention on
well-being and immune response in women with breast
cancer. This paper presents in-depth information on the
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the Consort recommendations [39-41].
Primary outcome
The efficacy of MBSR on mood disorders, evaluated in
terms of anxiety and depression.
Secondary outcomes
The efficacy of MBSR on:
 coping capacity,
 symptom experience,
 quality of life,
 health status,
 personal growth,
 level of mindfulness,
 physiological response, disease progression, survival,
 analyses of utility and health economics, and
 analyses of the usability of MBSR in clinical care.
Methods
Design
Patients diagnosed with early stage breast cancer will be
consecutively recruited from two surgical centers, toStudy information to women with breast cancer,
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Figure 1 Study design including enrollment, allocation and follow-upparticipate in this three-armed randomized controlled
complementary intervention study. The study design is
presented in Figure 1.
Written consent will be obtained before enrolment.
Confidentiality will be assured, and participants will be
advised that they are free to withdraw from the study at
any time, and respect will be given to the participant’s
condition. The study is registered in ClinicalTrials.gov:
NCT01591915.
Participants
In this randomized, controlled intervention study, pa-
tients diagnosed with breast cancer will be consecutively
recruited to participate after completion of adjuvant
chemotherapy, with/or without endocrine therapy.
Research nurses will contact eligible patients at the
first follow-up appointment for patients receiving hor-
monal therapy or at the last treatment for patients
undergoing chemotherapy. After oral and written infor-
mation, interested patients will provide written consent
to participate in the study. Participants who agree to
participate will be invited to a first baseline health
check-up appointment, including collection of blood
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Randomization will be conducted in blocks of 9, 12 and
15 blocks varied randomly. The assignment codes will be
kept in sequentially numbered, opaque, sealed envelopes,
prepared by the research team. At the time of allocation,
the research nurse will pick the sequential envelope, write
the participant’s name and personal registration number
on the envelope, and then open it.
Inclusion criteria
Patients diagnosed with early-stage breast cancer:
receiving hormonal therapy, or:
after completion of adjuvant chemotherapy,
with or without radiotherapy
Exclusion criteria
Patients with other advanced illness at diagnosis, and/or:
ongoing major depression
ongoing Herceptin therapy
previously use of MBSR
Training of instructors
Trained by a senior MBSR instructor, four registered
nurses, skilled in patient learning, have been trained as
certified MBSR instructors. Briefly, the instructor training
consists of: 1 day of introduction to MBSR; 8 weeks of in-
structors’ own MBSR practice including 20 minutes ses-
sions, 6 days/week; 2 days focused on practical training in
group sessions; 8 week course in leading a group of pa-
tients who attend once a week for an average of 2 hours;
2 days focused on instructors’ experience of leading pa-
tient groups; and 1 day examination and certification.
Intervention
It is well known that attention, expectations and good
caring treatment contribute to the placebo effect. In
order to minimize the impact of a situation with “a self-
selected treatment and caring response to an enthusias-
tic therapist may be part of the active components of the
alternative medical field” [42], two intervention groups
and one control group will be included. All women re-
ceive standard care (SC) according to the national and
local guidelines recommendations [43].
Participants will be randomized into one of three
groups:
– SC and MBSR Intervention group I (8 weeks
self-instructing program + instructor and weekly
group sessions)
– SC and MBSR Intervention group II (8 weeks
self-instructing program)
– SC and Non-MBSR (Controls)Participants in MBSR Intervention group I and
MBSR Intervention group II will participate in an 8-
week tutorial of MBSR practice with homework as-
signments consisting of 20 minutes sessions, 6 days/
week. Participants will be provided with information
material including a 20-page introduction to mindful-
ness training, CD, diary and training program. Only
participants in MBSR Intervention group I will take
part in a structured group-formatted 8-week course
that patients attend once a week for an average of
2 hours. Led by a certified MBSR instructor, these
weekly group sessions will be focused on the partici-
pant’s experience of mindfulness, and include gentle
yoga and meditation training. Owing to the differ-
ences between the two interventions groups, blinding
will not be possible.Data collection
Socio-demographic data will be collected through chart
review and interviews. Data characteristics are age,
marital status, living situation, employment status, chil-
dren, occupation and educational level. Clinical charac-
teristics investigated are type of treatment, tumor
characteristics, and co-morbidity. Patient self-reported
response (questionnaires) and immune response (blood
samples) will be collected, and health checks conducted,
at baseline (before start of intervention), after the inter-
vention for MBSR Intervention groups I and II, follow-
up will be conducted one months after the intervention,
and at similar time points of 3 months (non-MBSR),
6 months, 12 months, and thereafter yearly up to
5 years. Health checks including current health status
and treatment, and blood samples will be performed by
research nurses. Patient outcome will be collected by
following the questionnaires, health check-ups and bio-
markers.Measuring outcomes
Primary outcome
Mood disorder The Hospital Anxiety and Depression
Scale (HAD) is one of most widely used instruments to
screen for anxiety and depression or psychosocial dis-
tress in cancer patients [44-46]. HAD is a 14-item ques-
tionnaire consisting of two sub-scales, anxiety and
depression. Each response is rated on a four-point scale.
Subscale scores range from 0 to 21. Scores of 0–7 indi-
cate “normal”, 8–10 “borderline” and scores of >11 or
more on either sub-scale are considered to represent
risk of psychological morbidity [44-47]. The internal
consistency of reliability for HAD Depression and HAD
Anxiety are satisfactory, with Cronbach’s alpha 0.72 -
0.89, respectively 0.78 - 0.93 [46].
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Coping capacity Personal coping resources are evalu-
ated using the Sense of Coherence scale (SOC) [48,49].
The SOC short version scale consists of 13 items on a
7-point Likert scale. The SOC scale evaluates perceived
comprehensibility (5 items), manageability (4 items) and
meaningfulness (4 items). A higher score represents a
stronger sense of coherence [50]. The reliability and val-
idity of the SOC scale has been proven in many studies
and different languages with a Cronbach’s α range of
0.74 to 0.93 [51-53].
Symptom experience Symptoms (frequency, severity
and distress) are measured using the Memorial Symp-
tom Assessment Scale (MSAS), a multidimensional
questionnaire consisting of 32 symptoms [54]. The
MSAS generates the Total Symptom Burden Scale
(TMSAS) and the Global Symptom Distress Index
(GDI). The MSAS has been proven to be a reliable and
valid multidimensional measure of symptom experience
in cancer populations [54,55].
Health-related quality of life Breast cancer specific
HRQoL is evaluated using the 10 item visual analogue
scale of the International Breast Cancer Study Group
Quality of Life Core Questionnaire (IBCSG QoL). The
questionnaire includes global indicators for physical
well-being, mood, coping, social support and subjective
health estimation, and indicators of symptoms covering
possible specific disease and treatment-related effects.
Higher scores indicate a higher level of symptoms/prob-
lems. The reliability and validity of the questionnaire has
been established in several studies [56,57].
Health status The SF-36 measures eight domains of
health including physical functioning, role limitations
due to physical health, bodily pain, general health
perceptions, vitality, social functioning, role limitations
due to emotional problems, and mental health [58]. The
SF-36 yields a score for each of these eight domains, a
total score for physical and mental health, and a global
health utility index. Maximum score is 100 points.
Higher scores indicate better health status. The reliabil-
ity measurements of the SF-36 are consistently good
[58-61].
Personal growth Posttraumatic Growth Inventory (PTGI)
is a measure of positive life changes after traumatic or life-
altering events [62]. The PTGI consist of 21 items, rated
on a 6-point Likert scale, divided into five dimensions:
Relating to others (7 items), New possibilities (5 items),
Personal strength (4 items), Spiritual change (2 items), and
Appreciation of life (3 items). The PTGI yields a score for
each of these subscales, and a total score. The PTGI hasshown good reliability in previous research of breast
cancer survivors, with Cronbach’s alpha for the PGI
total score was 0.96 [63].Mindfulness Five Facets of Mindfulness Questionnaire
(FFMQ short form). FFMQ developed by Baer and col-
leagues [64]. The FFMQ short form consists of 29 items,
and yield five factors that appear to represent elements
of mindfulness as it is currently conceptualized: Observ-
ing, Describing, Acting with awareness, Non-judging of
inner experience and Non-reactivity to inner experience.Blood sampling NK cell function will be measured
using a newly developed assay called flow cytometric
assay of natural killer cell immune response in activated
whole blood (FANKIA; 1). Briefly the cell line K562 is
mixed with whole blood and the mix is centrifuged and
incubated in 37°C for 2 hours. After staining with an
antibody that recognizes K562, the number of remaining
K562 cells is determined using flow cytometry and the
lytic activity of the NK cells is calculated. Flow cytome-
try will be performed using a standard multicolour pro-
cedure to detect the main lymphocyte populations in
human blood. Staining for regulatory T cells will also be
performed. Cytokine analyses of IL-6 and IL-8 in serum
will be performed using the automatic enzyme immuno-
assay system Immulite 1000 according to the standard
procedure from the manufacturer.Health check-ups Research nurses will conduct health
check-ups including blood pressure and heart rate, at
baseline and follow-ups. A protocol for baseline socio-
demographics and medical characteristics, and follow-up
protocols for current medical conditions, including dis-
ease progression, will be used to report health status.Analyses of utility and health economics and usabil-
ity of MBSR The utility of MBSR in clinical settings,
and health economic impact and costs will be described
in relation to sick leave, health care patterns, drug costs
and mortality.Sample size calculation
To detect significant differences between three groups
(MBSR Intervention I and II, and non-MBSR): 50
participants per group (150 participants in total) are
needed in order to achieve a statistical power of 80%.
The power calculation was based on alpha of 0.05 and
expected mean effect size difference between the groups
(difference in change between baseline and 3 months
follow-up) being at least 1 unit at HAD-scale.
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Descriptive statistics will be used to summarize socio-
demographic and clinical characteristics. Pearson’s cor-
relation coefficient will be calculated to determine the
strength of relationships between selected variables. Uni-
variate and multivariate analyses of variance for repeated
measures (ANOVA/MANOVA) will be used to compare
between groups. For comparison of skewed variables, a
non-parametric test will be used. Regression analyses
will be used to identify predictors. In multivariable step-
wise procedures only variables that provide statistically
significant contributions will be included in the analyses
(p < 0.05).Interviews
With the purpose of exploring how participants experi-
ence the effects of MBSR on mood and HRQoL, inter-
views will be conducted. A further purpose, from a
patient perspective, is to examine whether MBSR is clin-
ically relevant as a complementary method in breast
cancer. With the purpose of describing the process over
time, repeated interviews will be conducted during and
after the intervention. Grounded theory is a qualitative
method tailored to exploring processes, actions and
meaning. It is a systematic method of comparative
analysis and a strategic method of generating theory
grounded in data [65,66].Quality aspects
The following competences are represented in the research
group: Research manager Elisabeth Kenne Sarenmalm,
RN, PhD, Adjunct Lecturer, Research and Development
Center, Skaraborg Hospital, Skövde, Institute of Health
and Caring Sciences, Sahlgrenska Academy at University
of Gothenburg, experienced in research in breast cancer
patients, expert in psycho-oncology, and a certified MBSR
instructor. Lena B Mårtensson, RNM, PhD, Associate
Professor, Schools of Life Sciences, University of Skövde,
and expert in randomized controlled trials in comple-
mentary methods. Stig B Holmberg, specialist in tumor
surgery, MD, Associate Professor, Breast Department,
SU/Sahlgrenska University Hospital, Gothenburg, med-
ical advisor, expert in international, randomized, con-
trolled breast cancer trials, and patient recruitment.
Bengt A Andersson, specialist in clinical immunology,
MD, Associate Professor, Immunological Laboratory,
SU/Sahlgrenska University Hospital, Gothenburg, clinical
immunological advisor and expert in stress and immune
response. Anders Odén, Professor in Biostatistics, at
Chalmers University of Technology, Gothenburg, statis-
tical advisor and expert in statistical methods, biostatis-
tics, statistical aspects of epidemiology. Ingrid Bergh,
RN, PhD, Professor, Schools of Life Sciences, Universityof Skövde, and expert in patient-reported outcomes
assessment.
The senior MBSR instructor will continue as a super-
visor during the intervention in order to support MBSR
instructors and establish internal validity. A research
controller, responsible for logistics and protocol moni-
toring, and coordinating follow-ups, provide guarantee
for sustainability. Four research nurses, responsible for
inclusion, randomization and health check-ups, is a
guarantee for continuity during follow-up. Finally, con-
tinuous monitoring will ensure that the intervention is
implemented according to protocol, and with inclusion
and exclusion of participants follow-up to avoid selec-
tion bias. Exclusion of patients, including reason for
exclusion, will be reported in a reject log. Process evalu-
ations will be conducted using intermittent checks in
order to assure that the intervention procedures are
performed correctly and follow the study protocol.Ethical considerations
In studies including patients diagnosed with a serious ill-
ness such as breast cancer, ethical problems may arise.
Fundamental ethical principles including respect for in-
dividuals, and not causing harm will be observed. The
risk of privacy intrusion is minimized by requiring in-
formed consent. Participation in the study is voluntary
and can always be discontinued if the patient so desires.
Responsiveness and flexibility about the patient’s condi-
tion and motivation for participating in the study will
considered. Ethical approval has been granted by the
Etichal Research Committee, University of Göteborg
D:nr 499–9; 12/11/2009. Approval has also been granted
by the medical directors of the participating hospitals.
All patient data from the study are confidential and no
unauthorized person will have access to this information.
In data processing, name and personal identity number
will be replaced by a code so that no individual can be
identified. Only the principal investigator of the study
will have access to the code key. In published study re-
ports, individuals will not be identified. Handling per-
sonal data in Sweden is governed by the Personal Data
Act [67]. All data will be computer processed and stored
for at least 10 years.
The blood samples will be stored encrypted, and will
not be directly traceable back to individuals. The sam-
ples, as well as a corresponding identification list (code
key), will be stored safely and separately. Samples may
be used only in ways to which the participants consen-
ted. They can only be made available to a new research
project after participants submit a new agreement
and/or approval is granted by the Ethical Research
Committee. The participant has the right to request,
without explanation, that samples be destroyed or
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Discussion
Women with breast cancer have unique rehabilitation
needs. As the most common invasive cancer disease
among women worldwide, a high frequency of both
physical and psychological problems follows breast
cancer diagnosis and treatment. The major goal of re-
habilitation is to help each patient to achieve maximal
function within the limitations imposed by the disease
and its subsequent treatment.
Beyond the physical challenges of the disease and its
subsequent treatment, breast cancer patients experience
a variety of emotional reactions and psychological symp-
toms, which may have a significant impact on quality of
life. Symptom relief and health promotion are central in
the care of women with breast cancer. The present study
may contribute to evidence-based knowledge concerning
the efficacy of mindfulness training to support patient
empowerment to regain health in a breast cancer dis-
ease. If MBSR is effective for symptom relief and quality
of life, the method will have significant clinical relevance
that may generate standard of care for patients with
breast cancer. If so, the method will also be of great
benefit to other patient groups. There is a substantial
body of research on disease and treatment of severe ill-
ness, but very few studies directly examine factors that
promote health. MBSR may promote health by engaging
and strengthening an individual’s internal resources for
optimizing recovery from illness, and it may also im-
prove the ability to cope with mood disturbance and
symptoms of stress.
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